TrialMedical oncology (Northwood, London, England)2007

Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.

M Albertsson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.